Skip to content
Clinical Trials – home

GALLIUM (68GA): A Diagnostic Tool for Various Medical Conditions

9 / 11
trials open to patients / all trials
7+
Countries

In short

Gallium (68Ga) is a radioactive isotope being extensively studied in clinical trials for its potential to revolutionize cancer diagnosis and treatment. This article explores various ongoing studies utilizing Gallium (68Ga) in positron emission tomography (PET) imaging for different types of cancers and other medical conditions. The research aims to improve diagnostic accuracy, assess treatment responses, and potentially guide personalized therapies.

Introduction

Gallium (68Ga) is an innovative diagnostic tool that is being studied for its potential to improve the detection and assessment of various medical conditions. This article will provide an overview of Gallium (68Ga), its uses, and what patients can expect when undergoing imaging procedures using this substance.

What is Gallium (68Ga)?

Gallium (68Ga) is a radioactive isotope of gallium that is used in medical imaging. It is typically combined with other substances to create specialized imaging agents. These agents are designed to target specific tissues or processes in the body, allowing doctors to visualize and assess various medical conditions.

How Does It Work?

Gallium (68Ga) works by emitting positrons, which are detected by a special camera in a PET (Positron Emission Tomography) scanner. When combined with specific targeting molecules, Gallium (68Ga) can be directed to bind to certain types of cells or tissues in the body. This allows doctors to create detailed images of these areas and detect abnormalities that might not be visible with other imaging techniques.

Medical Conditions Diagnosed Using Gallium (68Ga)

Research is ongoing to explore the potential of Gallium (68Ga) in diagnosing and assessing various medical conditions. Some of the areas being studied include:

  • Cancer: Gallium (68Ga) is being investigated for its ability to detect and stage different types of cancer, including:
    • Gastro-esophageal cancer
    • Breast cancer
    • Prostate cancer
    • Multiple myeloma
    • Rectal cancer
  • Crohn's Disease: Researchers are studying the use of Gallium (68Ga) to assess the healing of perianal fistulas in patients with Crohn's disease.
  • Primary Aldosteronism: Gallium (68Ga) imaging is being evaluated for its potential to identify unilateral adrenal secretion of aldosterone in patients with this condition.

Benefits of Gallium (68Ga) Imaging

Gallium (68Ga) imaging offers several potential benefits:

  • Improved detection: It may be more sensitive in detecting certain types of cancer or other abnormalities compared to conventional imaging techniques.
  • Better staging: For cancer patients, it could provide more accurate information about the extent of the disease, helping doctors plan the most appropriate treatment.
  • Non-invasive: The imaging procedure is non-invasive, requiring only an injection of the imaging agent.
  • Personalized medicine: By providing detailed information about a patient's condition, it could help doctors tailor treatments more effectively.

The Imaging Procedure

If you are scheduled for a Gallium (68Ga) imaging procedure, here's what you can expect:

  1. You will receive an injection of the Gallium (68Ga) imaging agent through an intravenous (IV) line.
  2. There will be a waiting period to allow the imaging agent to circulate through your body and accumulate in the target tissues. This can take anywhere from a few minutes to a couple of hours, depending on the specific procedure.
  3. You will then lie on a table that moves through a PET scanner. The scanner detects the radiation emitted by the Gallium (68Ga) and creates detailed images of your body.
  4. The scanning process usually takes about 30-60 minutes.
  5. After the scan, you can typically resume your normal activities, but you may be advised to drink plenty of water to help flush the radioactive material from your system.

Safety and Side Effects

Gallium (68Ga) imaging is generally considered safe. The amount of radiation exposure is relatively low and the body eliminates the radioactive material quickly. However, as with any medical procedure, there are some considerations:

  • Pregnant women should not undergo this procedure due to potential risks to the fetus.
  • Breastfeeding women may need to temporarily stop breastfeeding after the procedure.
  • Some people may experience mild side effects such as pain at the injection site, nausea, or headache, but these are typically rare and short-lived.

Conclusion

Gallium (68Ga) imaging is an exciting area of medical research that holds promise for improving the diagnosis and management of various conditions, particularly in oncology. As research continues, it may become an increasingly important tool in personalized medicine, helping doctors to provide more accurate diagnoses and tailored treatments. If you're scheduled for a Gallium (68Ga) imaging procedure, don't hesitate to discuss any questions or concerns with your healthcare provider.

Questions people often ask

Conditions where Gallium (68Ga) is being studied

Each condition opens its own overview and trial list

Trials with Gallium (68Ga)

Recruiting trials first

See all 11 →
Quick filters
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).